# EDGAR Filing Document

**Accession Number:** 0001472091
**File Stem:** 0001140361-26-016759
**Filing Date:** 2026-4
**Character Count:** 2532
**Document Hash:** 9b739b8ff33e777a6fa254d668523da3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-016759.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001140361-26-016759

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260424

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PDS Biotechnology Corp
- **CENTRAL INDEX KEY:** 0001472091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264231384
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 303A COLLEGE ROAD EAST
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 800-208-3343

**MAIL ADDRESS:**
- **STREET 1:** 303A COLLEGE ROAD EAST
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Edge Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20090911

------

#### PDS BIOTECHNOLOGY CORPORATION

#### 303A College Road East

#### Princeton, NJ 08540

April 24, 2026

#### VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Chris Edwards

---

| | |
|:---|:---|
| Re: | PDS Biotechnology Corporation |
|  | Registration Statement on Form S-3 |
|  | File No. 333-289942 |
|  | Request for Acceleration |

---

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, PDS Biotechnology Corporation (the "**Registrant**") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-289942), so that it may become effective at 5:00 p.m. Eastern Time on April 28, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via a telephone call to the staff.

The cooperation of the staff in meeting the timetable described above is very much appreciated.

Please call Patrick O'Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **PDS BIOTECHNOLOGY CORPORATION** | **PDS BIOTECHNOLOGY CORPORATION** |
| By: | /s/ Lars Boesgaard |
| Name: | Lars Boesgaard |
| Title: | Chief Financial Officer |

---

cc: Fahd Riaz, Esq., *DLA Piper LLP (US)* <br> Dylan Caplan, Esq., *DLA Piper LLP (US)*

------